

## Movement Disorders

**Supplementary Table 1: Performance of a sequential testing approach: Pill Questionnaire then Montreal Cognitive Assessment, Mini-Mental State Examination or Scales for Outcomes in Parkinson's disease-Cognition for identifying PD-MCI**

	CUT-OFF		No MCI	MCI	Sensitivity	Specificity	PPV	NPV
MoCA	24/25	Inaccurate on Pill Q and below Cut-off	2	16	27%	96%	89%	53%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	48	43				
	25/26	Inaccurate on Pill Q and ≤ Cut-off	2	20	34%	96%	91%	55%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	48	39				
	26/27	Inaccurate on Pill Q and ≤ Cut-off	2	22	37%	96%	92%	56%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	48	37				
27/28	Inaccurate on Pill Q and ≤ Cut-off	5	22	37%	90%	81%	55%	
	Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	45	37					
SCOPA-Cog	24/25	Inaccurate on Pill Q and ≤ Cut-off	2	13	22%	96%	87%	51%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	48	46				
	25/26	Inaccurate on Pill Q and ≤ Cut-off	3	15	25%	94%	83%	52%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	47	44				
	26/27	Inaccurate on Pill Q and ≤ Cut-off	5	17	29%	90%	77%	52%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	45	42				
27/28	Inaccurate on Pill Q and ≤ Cut-off	5	19	32%	90%	79%	53%	
	Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	45	40					
MMSE	27/28	Inaccurate on Pill Q and ≤ Cut-off	1	8	14%	98%	89%	49%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	49	51				
	28/29	Inaccurate on Pill Q and ≤ Cut-off	2	12	20%	96%	86%	51%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	48	47				
	29/30	Inaccurate on Pill Q and ≤ Cut-off	8	22	37%	84%	73%	53%
		Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	42	37				
30/31	Inaccurate on Pill Q and ≤ Cut-off	10	24	41%	80%	71%	53%	
	Accurate on Pill Q or Inaccurate Pill Q and > Cut-off	40	35					

Pill Q, Pill Questionnaire; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; SCOPA-Cog, Scales for Outcomes in Parkinson's disease-Cognition

## Movement Disorders

Supplementary Table 2: Neuropsychological and global cognitive test performance by reliability taking medications according to caregiver

	Scores (Z-scores for neuropsychological tests, absolute scores for MoCA and SCOPA-Cog)		
	Takes Medications Reliably without Supervision <sup>a</sup> (n=104)	Uncertain or Unable to Take Medications Reliably without Supervision <sup>b</sup> (n=5)	p value <sup>d</sup> Reliable vs Unreliable Reporting
<b>Memory (CVLT-II - Long Delay Free Recall)<sup>7</sup></b>	<b>0.08 ± 1.17</b>	<b>-1.00 ± 1.62</b>	<b>0.05</b>
Attention ( <i>Digit Span - Longest Span Forward</i> ) <sup>8</sup>	0.51 ± 0.92	0.71 ± 0.93	0.66
Executive Function-Working memory ( <i>Letter-Number Sequencing</i> ) <sup>8</sup>	0.39 ± 0.89	0.00 ± 0.85	0.34
<b>Executive Function – Cognitive Flexibility (<i>Visual Verbal Test – Total Number of Shifts</i>)<sup>9</sup></b>	<b>-1.68 ± 1.90</b>	<b>-3.91 ± 2.04</b>	<b>0.0001</b>
Executive Function – Inhibitory Control ( <i>Color-Word Interference – Time to Complete Condition 3</i> ) <sup>10</sup>	0.13 ± 1.13	0.07 ± 0.64	0.91
Processing Speed ( <i>Color-Word Interference – Time to Complete Condition 1</i> ) <sup>10</sup>	-0.03 ± 0.97	-0.53 ± 0.87	0.26
Visuospatial ( <i>Visuospatial - Judgement of Line Orientation</i> ) <sup>11</sup>	-0.46 ± 1.50	-0.73 ± 0.82	0.69
<b>Language (<i>Verbal Fluency - Category Fluency Condition</i>)<sup>10</sup></b>	<b>0.22 ± 1.27</b>	<b>-1.33 ± 1.35</b>	<b>0.009</b>
MoCA	25.1 ± 3.0	22.6 ± 2.6	0.07
<b>SCOPA-Cog</b>	<b>27.2 ± 5.4</b>	<b>22.2 ± 5.4</b>	<b>0.05</b>

Values shown in bold type show statistically significant differences between groups.

<sup>a</sup> Rating 1, 2a

<sup>b</sup> Ratings 2b, 2c or 3

MDS-UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; SCOPA-Cog, Scales for Outcomes in Parkinson's disease-Cognition